Trial site
Hôpital Nord Franche-Comté
Montbéliard, 25250, FranceNot linked to an institution yet
- 10running trials
- 4closed trials
The trials here
What the 14 trials at this site are about, from their registry records.
- Phase
- Phase 210 trials
- Phase 2/31 trial
- Phase 31 trial
- Status
- Recruiting5 trials
- Active, not recruiting4 trials
- Completed2 trials
- Terminated2 trials
- Not yet recruiting1 trial
- Lead sponsor
- Centre Hospitalier Universitaire de Besancon8 trials
- Centre Hospitalier Universitaire De Dijon1 trial
- EMD Serono Research & Development Institute, Inc.1 trial
- Federation Francophone de Cancerologie Digestive1 trial
- GERCOR - Multidisciplinary Oncology Cooperative Group1 trial
- and 2 more
Running trials
Recruiting
PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatellite unstable or mismatch repair-deficient locally advanced rectal cancer patients: a randomized phase II trial
2024-510772-20-00· Phase 2· Centre Hospitalier Universitaire De Dijon· Source
Recruiting
Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers
NCT06425133· Phase 2· Centre Hospitalier Universitaire de Besancon· Source
Contact: Christophe BORG, Pr
Active, not recruiting
Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer
NCT05476796· Phase 2· UNICANCER· Source
Active, not recruiting
Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer
NCT05462613· Phase 2/3· Centre Hospitalier Universitaire de Besancon· Source
Recruiting
Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer
NCT05706779· Phase 2· Federation Francophone de Cancerologie Digestive· Source
Recruiting
Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
NCT05528952· Phase 2· Centre Hospitalier Universitaire de Besancon· Source
Contact: Serge FRATTE, Dr
Active, not recruiting
Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.
NCT04719988· Phase 2· Centre Hospitalier Universitaire de Besancon· Source
Recruiting
Exploratory Study of the Relevance of a Blood Test in the Management of Patients in the Context of Colorectal Cancer Screening
NCT04767568· Centre Hospitalier Universitaire de Besancon· Source
Contact: Christophe BORG, Pr
Active, not recruiting
LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy
NCT04166604· Phase 2· GERCOR - Multidisciplinary Oncology Cooperative Group· Source
Active, not recruiting
Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC
NCT03070366· Phase 2· Groupe Oncologie Radiotherapie Tete et Cou· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error